These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27103404)

  • 1. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
    Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
    Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
    Hekman MC; Rijpkema M; Muselaers CH; Oosterwijk E; Hulsbergen-Van de Kaa CA; Boerman OC; Oyen WJ; Langenhuijsen JF; Mulders PF
    Theranostics; 2018; 8(8):2161-2170. PubMed ID: 29721070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250.
    Muselaers CH; Rijpkema M; Bos DL; Langenhuijsen JF; Oyen WJ; Mulders PF; Oosterwijk E; Boerman OC
    J Urol; 2015 Aug; 194(2):532-8. PubMed ID: 25686542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
    Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron Emission Tomography/Computed Tomography with
    Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
    Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with
    van Oostenbrugge TJ; Langenhuijsen JF; Oosterwijk E; Boerman OC; Jenniskens SF; Oyen WJG; Fütterer JJ; Mulders PFA
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1864-1870. PubMed ID: 31768601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
    Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
    JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
    Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
    Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
    Yang X; Minn I; Rowe SP; Banerjee SR; Gorin MA; Brummet M; Lee HS; Koo SM; Sysa-Shah P; Mease RC; Nimmagadda S; Allaf ME; Pomper MG
    Oncotarget; 2015 Oct; 6(32):33733-42. PubMed ID: 26418876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
    Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
    Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Shuch B; Pantuck AJ; Bernhard JC; Morris MA; Master V; Scott AM; van Praet C; Bailly C; Önal B; Aksoy T; Merkx R; Schuster DM; Lee ST; Pandit-Taskar N; Fan AC; Allman P; Schmidt K; Tauchmanova L; Wheatcroft M; Behrenbruch C; Hayward CRW; Mulders P
    Lancet Oncol; 2024 Oct; 25(10):1277-1287. PubMed ID: 39270701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab.
    van Oostenbrugge T; Mulders P
    Curr Opin Urol; 2021 May; 31(3):249-254. PubMed ID: 33742975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
    Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
    Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.